Acquired resistance to PD-L1 inhibition is associated with an enhanced type I IFN-stimulated secretory program in tumor cells - Inria - Institut national de recherche en sciences et technologies du numérique Accéder directement au contenu
Pré-Publication, Document De Travail Année : 2021

Acquired resistance to PD-L1 inhibition is associated with an enhanced type I IFN-stimulated secretory program in tumor cells

Résumé

Background: Interferon (IFN) pathway activation in tumors can have dual, sometimes opposing, influences on immune responses. Therapeutic inhibition of programmed cell death ligand (PD-L1)-a treatment that reverses PD-1-mediated suppression of tumor-killing T-cells-is linked to alterations in IFN signaling; however, less is known about the role of IFNs after treatment resistance. Since IFN-regulated intracellular signaling can control extracellular secretory programs in tumors to modulate immunity, we examined the consequences of PD-L1 blockade on IFNrelated secretory changes in preclinical models of acquired resistance.

Domaines

Cancer
Fichier principal
Vignette du fichier
2021.07.01.450417v2.full.pdf (4.48 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-04387866 , version 1 (11-01-2024)

Licence

Paternité

Identifiants

Citer

Yuhao Shi, Melissa Dolan, Michalis Mastri, Amber Mckenery, James W Hill, et al.. Acquired resistance to PD-L1 inhibition is associated with an enhanced type I IFN-stimulated secretory program in tumor cells. 2023. ⟨hal-04387866⟩
23 Consultations
4 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More